Newly Characterized Murine Undifferentiated Sarcoma Models Sensitive to Virotherapy with Oncolytic HSV-1 M002

Eric Kohl Ring, Rong Li, Blake P. Moore, Li Nan, Virginia M. Kelly, Xiaosi Han, Elizabeth A. Beierle, James M. Markert, Jianmei W. Leavenworth, G. Yancey Gillespie, Gregory K. Friedman

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Despite advances in conventional chemotherapy, surgical techniques, and radiation, outcomes for patients with relapsed, refractory, or metastatic soft tissue sarcomas are dismal. Survivors often suffer from lasting morbidity from current treatments. New targeted therapies with less toxicity, such as those that harness the immune system, and immunocompetent murine sarcoma models to test these therapies are greatly needed. We characterized two new serendipitous murine models of undifferentiated sarcoma (SARC-28 and SARC-45) and tested their sensitivity to virotherapy with oncolytic herpes simplex virus 1 (HSV-1). Both models expressed high levels of the primary HSV entry molecule nectin-1 (CD111) and were susceptible to killing by interleukin-12 (IL-12) producing HSV-1 M002 in vitro and in vivo. M002 resulted in a significant intratumoral increase in effector CD4+ and CD8+ T cells and activated monocytes, and a decrease in myeloid-derived suppressor cells (MDSCs) in immunocompetent mice. Compared to parent virus R3659 (no IL-12 production), M002 resulted in higher CD8:MDSC and CD8:T regulatory cell (Treg) ratios, suggesting that M002 creates a more favorable immune tumor microenvironment. These data provide support for clinical trials targeting sarcomas with oncolytic HSV-1. These models provide an exciting opportunity to explore combination therapies for soft tissue sarcomas that rely on an intact immune system to reach full therapeutic potential.

Original languageEnglish (US)
Pages (from-to)27-36
Number of pages10
JournalMolecular Therapy - Oncolytics
Volume7
DOIs
StatePublished - Dec 15 2017

Fingerprint

Oncolytic Viruses
Human Herpesvirus 1
Sarcoma
Interleukin-12
Immune System
Therapeutics
Tumor Microenvironment
Regulatory T-Lymphocytes
Survivors
Monocytes
Clinical Trials
Radiation
Viruses
Morbidity
T-Lymphocytes
Drug Therapy

Keywords

  • HSV
  • M002
  • herpes simplex virus
  • immunotherapy
  • murine sarcoma
  • oncolytic

ASJC Scopus subject areas

  • Molecular Medicine
  • Oncology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Newly Characterized Murine Undifferentiated Sarcoma Models Sensitive to Virotherapy with Oncolytic HSV-1 M002. / Ring, Eric Kohl; Li, Rong; Moore, Blake P.; Nan, Li; Kelly, Virginia M.; Han, Xiaosi; Beierle, Elizabeth A.; Markert, James M.; Leavenworth, Jianmei W.; Gillespie, G. Yancey; Friedman, Gregory K.

In: Molecular Therapy - Oncolytics, Vol. 7, 15.12.2017, p. 27-36.

Research output: Contribution to journalArticle

Ring, EK, Li, R, Moore, BP, Nan, L, Kelly, VM, Han, X, Beierle, EA, Markert, JM, Leavenworth, JW, Gillespie, GY & Friedman, GK 2017, 'Newly Characterized Murine Undifferentiated Sarcoma Models Sensitive to Virotherapy with Oncolytic HSV-1 M002', Molecular Therapy - Oncolytics, vol. 7, pp. 27-36. https://doi.org/10.1016/j.omto.2017.09.003
Ring, Eric Kohl ; Li, Rong ; Moore, Blake P. ; Nan, Li ; Kelly, Virginia M. ; Han, Xiaosi ; Beierle, Elizabeth A. ; Markert, James M. ; Leavenworth, Jianmei W. ; Gillespie, G. Yancey ; Friedman, Gregory K. / Newly Characterized Murine Undifferentiated Sarcoma Models Sensitive to Virotherapy with Oncolytic HSV-1 M002. In: Molecular Therapy - Oncolytics. 2017 ; Vol. 7. pp. 27-36.
@article{348bb555d4384098a819fede2f273c23,
title = "Newly Characterized Murine Undifferentiated Sarcoma Models Sensitive to Virotherapy with Oncolytic HSV-1 M002",
abstract = "Despite advances in conventional chemotherapy, surgical techniques, and radiation, outcomes for patients with relapsed, refractory, or metastatic soft tissue sarcomas are dismal. Survivors often suffer from lasting morbidity from current treatments. New targeted therapies with less toxicity, such as those that harness the immune system, and immunocompetent murine sarcoma models to test these therapies are greatly needed. We characterized two new serendipitous murine models of undifferentiated sarcoma (SARC-28 and SARC-45) and tested their sensitivity to virotherapy with oncolytic herpes simplex virus 1 (HSV-1). Both models expressed high levels of the primary HSV entry molecule nectin-1 (CD111) and were susceptible to killing by interleukin-12 (IL-12) producing HSV-1 M002 in vitro and in vivo. M002 resulted in a significant intratumoral increase in effector CD4+ and CD8+ T cells and activated monocytes, and a decrease in myeloid-derived suppressor cells (MDSCs) in immunocompetent mice. Compared to parent virus R3659 (no IL-12 production), M002 resulted in higher CD8:MDSC and CD8:T regulatory cell (Treg) ratios, suggesting that M002 creates a more favorable immune tumor microenvironment. These data provide support for clinical trials targeting sarcomas with oncolytic HSV-1. These models provide an exciting opportunity to explore combination therapies for soft tissue sarcomas that rely on an intact immune system to reach full therapeutic potential.",
keywords = "HSV, M002, herpes simplex virus, immunotherapy, murine sarcoma, oncolytic",
author = "Ring, {Eric Kohl} and Rong Li and Moore, {Blake P.} and Li Nan and Kelly, {Virginia M.} and Xiaosi Han and Beierle, {Elizabeth A.} and Markert, {James M.} and Leavenworth, {Jianmei W.} and Gillespie, {G. Yancey} and Friedman, {Gregory K.}",
year = "2017",
month = "12",
day = "15",
doi = "10.1016/j.omto.2017.09.003",
language = "English (US)",
volume = "7",
pages = "27--36",
journal = "Molecular Therapy - Oncolytics",
issn = "2372-7705",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Newly Characterized Murine Undifferentiated Sarcoma Models Sensitive to Virotherapy with Oncolytic HSV-1 M002

AU - Ring, Eric Kohl

AU - Li, Rong

AU - Moore, Blake P.

AU - Nan, Li

AU - Kelly, Virginia M.

AU - Han, Xiaosi

AU - Beierle, Elizabeth A.

AU - Markert, James M.

AU - Leavenworth, Jianmei W.

AU - Gillespie, G. Yancey

AU - Friedman, Gregory K.

PY - 2017/12/15

Y1 - 2017/12/15

N2 - Despite advances in conventional chemotherapy, surgical techniques, and radiation, outcomes for patients with relapsed, refractory, or metastatic soft tissue sarcomas are dismal. Survivors often suffer from lasting morbidity from current treatments. New targeted therapies with less toxicity, such as those that harness the immune system, and immunocompetent murine sarcoma models to test these therapies are greatly needed. We characterized two new serendipitous murine models of undifferentiated sarcoma (SARC-28 and SARC-45) and tested their sensitivity to virotherapy with oncolytic herpes simplex virus 1 (HSV-1). Both models expressed high levels of the primary HSV entry molecule nectin-1 (CD111) and were susceptible to killing by interleukin-12 (IL-12) producing HSV-1 M002 in vitro and in vivo. M002 resulted in a significant intratumoral increase in effector CD4+ and CD8+ T cells and activated monocytes, and a decrease in myeloid-derived suppressor cells (MDSCs) in immunocompetent mice. Compared to parent virus R3659 (no IL-12 production), M002 resulted in higher CD8:MDSC and CD8:T regulatory cell (Treg) ratios, suggesting that M002 creates a more favorable immune tumor microenvironment. These data provide support for clinical trials targeting sarcomas with oncolytic HSV-1. These models provide an exciting opportunity to explore combination therapies for soft tissue sarcomas that rely on an intact immune system to reach full therapeutic potential.

AB - Despite advances in conventional chemotherapy, surgical techniques, and radiation, outcomes for patients with relapsed, refractory, or metastatic soft tissue sarcomas are dismal. Survivors often suffer from lasting morbidity from current treatments. New targeted therapies with less toxicity, such as those that harness the immune system, and immunocompetent murine sarcoma models to test these therapies are greatly needed. We characterized two new serendipitous murine models of undifferentiated sarcoma (SARC-28 and SARC-45) and tested their sensitivity to virotherapy with oncolytic herpes simplex virus 1 (HSV-1). Both models expressed high levels of the primary HSV entry molecule nectin-1 (CD111) and were susceptible to killing by interleukin-12 (IL-12) producing HSV-1 M002 in vitro and in vivo. M002 resulted in a significant intratumoral increase in effector CD4+ and CD8+ T cells and activated monocytes, and a decrease in myeloid-derived suppressor cells (MDSCs) in immunocompetent mice. Compared to parent virus R3659 (no IL-12 production), M002 resulted in higher CD8:MDSC and CD8:T regulatory cell (Treg) ratios, suggesting that M002 creates a more favorable immune tumor microenvironment. These data provide support for clinical trials targeting sarcomas with oncolytic HSV-1. These models provide an exciting opportunity to explore combination therapies for soft tissue sarcomas that rely on an intact immune system to reach full therapeutic potential.

KW - HSV

KW - M002

KW - herpes simplex virus

KW - immunotherapy

KW - murine sarcoma

KW - oncolytic

UR - http://www.scopus.com/inward/record.url?scp=85041115659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041115659&partnerID=8YFLogxK

U2 - 10.1016/j.omto.2017.09.003

DO - 10.1016/j.omto.2017.09.003

M3 - Article

VL - 7

SP - 27

EP - 36

JO - Molecular Therapy - Oncolytics

JF - Molecular Therapy - Oncolytics

SN - 2372-7705

ER -